SE370449B
(en)
|
1970-08-29 |
1974-10-14 |
Philips Nv |
|
JPS5334319B2
(en)
|
1971-12-28 |
1978-09-20 |
|
|
JPS5717624B2
(en)
|
1974-04-17 |
1982-04-12 |
|
|
US4208479A
(en)
|
1977-07-14 |
1980-06-17 |
Syva Company |
Label modified immunoassays
|
JPS5912436B2
(en)
|
1980-08-05 |
1984-03-23 |
ファナック株式会社 |
Industrial robot safety mechanism
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JPH0234615Y2
(en)
|
1986-08-08 |
1990-09-18 |
|
|
JPH06104071B2
(en)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
Factor IX Monoclonal antibody specific for conformation
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
JPS6459878A
(en)
|
1987-08-31 |
1989-03-07 |
Matsushita Electric Ind Co Ltd |
Semiconductor laser protective circuit
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
IL89491A0
(en)
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Bifunctional chimeric antibodies
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
JPH0341033A
(en)
|
1989-07-07 |
1991-02-21 |
Kyowa Hakko Kogyo Co Ltd |
Stable preparation containing motilins
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
AU649952B2
(en)
|
1989-12-11 |
1994-06-09 |
Immunomedics Inc. |
Method for antibody targeting of diagnostic or therapeutic agents
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
TW212184B
(en)
|
1990-04-02 |
1993-09-01 |
Takeda Pharm Industry Co Ltd |
|
JPH05184383A
(en)
|
1990-06-19 |
1993-07-27 |
Dainabotsuto Kk |
Bispecific antibody
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
JPH05199894A
(en)
|
1990-08-20 |
1993-08-10 |
Takeda Chem Ind Ltd |
Bi-specific antibody and antibody-containing medicine
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DE69133476T2
(en)
|
1990-08-29 |
2006-01-05 |
GenPharm International, Inc., Palo Alto |
Transgenic mice capable of producing heterologous antibodies
|
ES2134212T3
(en)
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN.
|
JPH05304992A
(en)
|
1991-06-20 |
1993-11-19 |
Takeda Chem Ind Ltd |
Hybridoma-monoclonal antibody and medicine containing antibody
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
CA2119930C
(en)
|
1991-09-23 |
2002-10-01 |
Hendricus R. J. M. Hoogenboom |
Production of chimeric antibodies - a combinatorial approach
|
ATE207080T1
(en)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
MULTIVALENT ANTIGEN-BINDING PROTEINS
|
ES2227512T3
(en)
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
JPH05203652A
(en)
|
1992-01-28 |
1993-08-10 |
Fuji Photo Film Co Ltd |
Antibody enzyme immunoassay
|
JPH05213775A
(en)
|
1992-02-05 |
1993-08-24 |
Otsuka Pharmaceut Co Ltd |
Bfa antibody
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
WO1993019172A1
(en)
|
1992-03-24 |
1993-09-30 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US5744446A
(en)
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
EP0627932B1
(en)
|
1992-11-04 |
2002-05-08 |
City Of Hope |
Antibody construct
|
JP3720353B2
(en)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
Multivalent and multispecific binding proteins, their production and use
|
ATE187494T1
(en)
|
1992-12-11 |
1999-12-15 |
Dow Chemical Co |
MULTIVALENT SINGLE CHAIN ANTIBODIES
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
EP0660937A1
(en)
|
1993-07-01 |
1995-07-05 |
Dade International Inc. |
Process for the preparation of factor x depleted plasma
|
UA40577C2
(en)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
CA2177988A1
(en)
|
1993-12-03 |
1995-06-08 |
Kazuo Higuchi |
Expression vector for preparing an anti-body-variable-region library
|
WO1995015388A1
(en)
|
1993-12-03 |
1995-06-08 |
Medical Research Council |
Recombinant binding proteins and peptides
|
DE122009000068I2
(en)
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Process for the preparation of heterologous bispecific antibodies
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
DK0771216T3
(en)
|
1994-07-11 |
2001-02-05 |
Scripps Research Inst |
Methods and preparations for specific coagulation of tumor vasculature
|
CA2194907A1
(en)
|
1994-07-13 |
1996-02-01 |
Kouji Matsushima |
Reshaped human antibody against human interleukin-8
|
AU3272695A
(en)
|
1994-08-12 |
1996-03-07 |
Immunomedics Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6451523B1
(en)
|
1994-09-14 |
2002-09-17 |
Interneuron Pharmaceuticals, Inc. |
Detection of a leptin receptor variant and methods for regulating obesity
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
AU700819B2
(en)
|
1994-10-07 |
1999-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
|
PL182089B1
(en)
|
1994-10-21 |
2001-11-30 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutic compositions for treating diseases caused by production of il-6
|
AU4289496A
(en)
|
1994-12-02 |
1996-06-19 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
ES2152514T3
(en)
|
1995-02-28 |
2001-02-01 |
Procter & Gamble |
PREPARATION OF NON CARBONED BEVERAGE PRODUCTS THAT HAVE SUPERIOR MICROBIAL STABILITY.
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
DE69636015T2
(en)
|
1995-05-03 |
2007-01-04 |
Bioenhancementsments Ltd. |
BIS-SPECIFIC ANTIBODIES IN WHICH THE BINDING ABILITY IS INHERITIZED BY A MEDIUM-SPLITABLE GROUP REVERSIBLE
|
JP3946256B2
(en)
|
1995-09-11 |
2007-07-18 |
協和醗酵工業株式会社 |
Antibody to human interleukin 5 receptor α chain
|
JP2000503204A
(en)
|
1996-01-08 |
2000-03-21 |
ジェネンテック インコーポレーテッド |
WSX receptor and ligands
|
MA24512A1
(en)
|
1996-01-17 |
1998-12-31 |
Univ Vermont And State Agrienl |
PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS
|
FR2745008A1
(en)
|
1996-02-20 |
1997-08-22 |
Ass Pour Le Dev De La Rech En |
MODIFIED NUCLEAR GLUCOCORTICOID RECEPTOR, DNA FRAGMENTS ENCODING SAID RECEPTOR, AND METHODS IN WHICH THEY ARE USED
|
JP3032287U
(en)
|
1996-06-10 |
1996-12-17 |
幸喜 高橋 |
Human form
|
US20020147326A1
(en)
|
1996-06-14 |
2002-10-10 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
AU720232B2
(en)
|
1996-07-19 |
2000-05-25 |
Amgen, Inc. |
Analogs of cationic proteins
|
AU744146B2
(en)
|
1996-09-26 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against human parathormone related peptides
|
JPH10165184A
(en)
|
1996-12-16 |
1998-06-23 |
Tosoh Corp |
Antibody, gene and production of chimera antibody
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6323000B2
(en)
|
1996-12-20 |
2001-11-27 |
Clark A. Briggs |
Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
|
ES2300122T3
(en)
|
1997-03-20 |
2008-06-01 |
The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services |
RECOMBINANT AND IMMUNOCATED PLAYING ANTIBODIES AGAINST CD-22 CARRIER CELLS AND TUMORS.
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
FR2761994B1
(en)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
ATE299938T1
(en)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
DE19725586C2
(en)
|
1997-06-17 |
1999-06-24 |
Gsf Forschungszentrum Umwelt |
Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies
|
US6368596B1
(en)
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
AU750453B2
(en)
|
1997-10-03 |
2002-07-18 |
Chugai Seiyaku Kabushiki Kaisha |
Natural human antibody
|
ATE383875T1
(en)
|
1998-03-17 |
2008-02-15 |
Chugai Pharmaceutical Co Ltd |
PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT CONTAINING ANTAGONISTIC IL-6 RECEPTOR ANTIBODIES
|
BR9909382A
(en)
|
1998-04-03 |
2000-12-05 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor (tf) and humanized antibody production process
|
DE19819846B4
(en)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalent antibody constructs
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US7081360B2
(en)
|
1998-07-28 |
2006-07-25 |
Cadus Technologies, Inc. |
Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
ATE477273T1
(en)
|
1998-12-01 |
2010-08-15 |
Facet Biotech Corp |
HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL220113B1
(en)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
CO5280147A1
(en)
|
1999-05-18 |
2003-05-30 |
Smithkline Beecham Corp |
MONOCLONAL HUMAN ANTIBODY
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
AT411997B
(en)
|
1999-09-14 |
2004-08-26 |
Baxter Ag |
FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES
|
SE9903895D0
(en)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
US20020028178A1
(en)
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
AU1290001A
(en)
|
1999-11-18 |
2001-05-30 |
Oxford Biomedica (Uk) Limited |
Antibodies
|
CA2390662A1
(en)
|
1999-12-14 |
2001-06-21 |
The Burnham Institute |
Bcl-g polypeptides, encoding nucleic acids and methods of use
|
AU2001256174A1
(en)
|
2000-03-01 |
2001-09-12 |
Christoph Gasche |
Mammalian interleukin-10 (il-10) receptor variants
|
TWI242043B
(en)
|
2000-03-10 |
2005-10-21 |
Chugai Pharmaceutical Co Ltd |
Polypeptide inducing apoptosis
|
AU4778101A
(en)
|
2000-03-22 |
2001-10-03 |
Curagen Corp |
Novel polypeptides, and nucleic acids encoding the same
|
CN1981868A
(en)
|
2000-03-31 |
2007-06-20 |
拜奥根Idec公司 |
Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
|
WO2001075454A2
(en)
|
2000-04-03 |
2001-10-11 |
Oxford Glycosciences (Uk) Ltd. |
Diagnosis and treatment of alzheimer's disease
|
WO2001079494A1
(en)
|
2000-04-17 |
2001-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Agonist antibodies
|
AU2001266272B2
(en)
|
2000-05-03 |
2005-09-15 |
Medigene Ag |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
JP2004511430A
(en)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
Bispecific immunoglobulin-like antigen binding protein and production method
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
SG136804A1
(en)
|
2000-07-12 |
2007-11-29 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
JP4908721B2
(en)
|
2000-07-17 |
2012-04-04 |
中外製薬株式会社 |
Screening method for ligands having physiological activity
|
MXPA03002262A
(en)
|
2000-09-18 |
2003-10-15 |
Idec Pharma Corp |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
|
PT1324776E
(en)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
RU2287534C2
(en)
|
2000-10-20 |
2006-11-20 |
Тугаи Сейяку Кабусики Кайся |
Degraded antibody as tpo agonist
|
EP1327680B1
(en)
|
2000-10-20 |
2008-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Modified tpo agonist antibody
|
CA2424371A1
(en)
|
2000-10-20 |
2003-04-01 |
Chugai Seiyaku Kabushiki Kaisha |
Agonistic monoclonal antibody fragments
|
CN1308447C
(en)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
Degraded agonist antibody
|
WO2002036165A1
(en)
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
ES2727425T3
(en)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Molecules with prolonged half-lives, compositions and uses thereof
|
KR20090010127A
(en)
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
AU2002307062A1
(en)
|
2001-04-02 |
2002-10-15 |
Purdue Pharma L.P. |
Thrombopoietin (tpo) synthebody for stimulation of platelet production
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
SK288124B6
(en)
|
2001-04-13 |
2013-09-03 |
Biogen Idec Ma Inc. |
Anti-VLA-1 antibody, composition comprising such antibodies, isolated nucleic acids sequence, use of composition, in vitro method of determining level of VLA-1 in tissue, cell of cell line hAQC2, haAQC2, hsAQC2 or hybridoma mAQC2 and method for identifying inhibitor of I domain of integrin
|
JP4281869B2
(en)
|
2001-06-22 |
2009-06-17 |
中外製薬株式会社 |
Cell growth inhibitor containing anti-glypican 3 antibody
|
AU2002319402B2
(en)
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
BR0213303A
(en)
|
2001-10-15 |
2005-06-07 |
Immunomedics Inc |
Direct Bleach Binding Proteins
|
WO2003035835A2
(en)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
DE10156482A1
(en)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispecific antibody molecule
|
MXPA04007583A
(en)
|
2002-02-11 |
2005-04-25 |
Genentech Inc |
Antibody variants with faster antigen association rates.
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
AU2003227504A1
(en)
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
US7732149B2
(en)
|
2002-04-26 |
2010-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening agonistic antibodies
|
US20050130224A1
(en)
|
2002-05-31 |
2005-06-16 |
Celestar Lexico- Sciences, Inc. |
Interaction predicting device
|
JP2004086862A
(en)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
Apparatus, method and program for processing protein interaction information, and recording medium
|
WO2003104425A2
(en)
|
2002-06-07 |
2003-12-18 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Novel stable anti-cd22 antibodies
|
CA2488836A1
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
PT2314629E
(en)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Recombinant production of mixtures of antibodies
|
CA2492524A1
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
JP2004086682A
(en)
|
2002-08-28 |
2004-03-18 |
Fujitsu Ltd |
Functional block design method and functional block design device
|
EP1561759B9
(en)
|
2002-10-11 |
2009-08-26 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death-inducing agent
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
EP1562972B1
(en)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
GB0224082D0
(en)
|
2002-10-16 |
2002-11-27 |
Celltech R&D Ltd |
Biological products
|
NZ540730A
(en)
|
2002-12-24 |
2010-09-30 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
WO2004060919A1
(en)
|
2002-12-26 |
2004-07-22 |
Chugai Seiyaku Kabushiki Kaisha |
Agonist antibody against heteroreceptor
|
US8337841B2
(en)
|
2003-01-21 |
2012-12-25 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening for antibody light chains
|
US7223393B2
(en)
|
2003-02-07 |
2007-05-29 |
Pdl Biopharma, Inc |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP4739954B2
(en)
|
2003-03-13 |
2011-08-03 |
中外製薬株式会社 |
Ligands with agonist activity for mutant receptors
|
JP2004279086A
(en)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
Radiation image conversion panel and method for manufacturing it
|
US20070003556A1
(en)
|
2003-03-31 |
2007-01-04 |
Masayuki Tsuchiya |
Modified antibodies against cd22 and utilization thereof
|
GB2400851B
(en)
|
2003-04-25 |
2004-12-15 |
Bioinvent Int Ab |
Identifying binding of a polypeptide to a polypeptide target
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
KR20160114727A
(en)
|
2003-05-30 |
2016-10-05 |
제넨테크, 인크. |
Treatment with anti-VEGF antibodies
|
EP1629001A2
(en)
|
2003-06-05 |
2006-03-01 |
Genentech, Inc. |
Blys antagonists and uses thereof
|
US8597911B2
(en)
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
EP1636264A2
(en)
|
2003-06-24 |
2006-03-22 |
MERCK PATENT GmbH |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
EP1644416A4
(en)
|
2003-06-30 |
2007-08-29 |
Centocor Inc |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
US7297336B2
(en)
|
2003-09-12 |
2007-11-20 |
Baxter International Inc. |
Factor IXa specific antibodies displaying factor VIIIa like activity
|
JP2005101105A
(en)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
Positioning device, exposure apparatus, and device manufacturing method
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
WO2005035753A1
(en)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2311945A1
(en)
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies substituting for functional proteins
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US20050142133A1
(en)
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
KR20130133302A
(en)
|
2003-12-10 |
2013-12-06 |
메다렉스, 인코포레이티드 |
Ip-10 antibodies and their uses
|
EP1711207B1
(en)
|
2003-12-10 |
2012-11-28 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
EP1710255A4
(en)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
Modified antibodies recognising receptor trimers or higher multimers
|
WO2005056602A1
(en)
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Method of screening modified antibody having agonistic activity
|
TW200530266A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Method of reinforcing antibody activity
|
AR048210A1
(en)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
A PREVENTIVE AGENT FOR VASCULITIS.
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
UA93027C2
(en)
|
2003-12-25 |
2011-01-10 |
Киова Хакко Кирин Ко., Лимитед |
Mutant antibody, which specifically binds to cd40
|
DE602004013372T2
(en)
|
2003-12-30 |
2009-07-02 |
Merck Patent Gmbh |
IL-7 FUSION PROTEINS WITH ANTIBODY PORTIONS, THEIR PREPARATION AND THEIR USE
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
CA2552523C
(en)
|
2004-01-09 |
2019-11-26 |
Pfizer Inc. |
Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
|
AR048335A1
(en)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
TW200605906A
(en)
|
2004-05-11 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Remedy for thrombopenia
|
KR100620554B1
(en)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
-72 Humanized Anti-TAG-72 Monoclonal Antibodies
|
AR049390A1
(en)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
|
AU2005259992A1
(en)
|
2004-06-25 |
2006-01-12 |
Medimmune, Llc |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
DE102004032634A1
(en)
|
2004-07-06 |
2006-02-16 |
Sms Demag Ag |
Method and device for measuring and controlling the flatness and / or the strip tensions of a stainless steel strip or a stainless steel foil during cold rolling in a multi-roll stand, in particular in a 20-roll Sendizimir rolling mill
|
PL1674111T3
(en)
|
2004-07-09 |
2011-04-29 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
CA2577082A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
MX2007002883A
(en)
|
2004-09-13 |
2007-06-15 |
Macrogenics Inc |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof.
|
CA2580319A1
(en)
|
2004-09-14 |
2006-03-23 |
National Institute For Biological Standards And Control |
Vaccine
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
WO2006033386A1
(en)
|
2004-09-22 |
2006-03-30 |
Kirin Beer Kabushiki Kaisha |
STABILIZED HUMAN IgG4 ANTIBODIES
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
CA2584211C
(en)
|
2004-10-22 |
2014-07-08 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
AU2005317279C1
(en)
|
2004-12-14 |
2014-07-17 |
Cytiva Bioprocess R&D Ab |
Purification of immunoglobulins
|
US8728828B2
(en)
|
2004-12-22 |
2014-05-20 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
WO2006067847A1
(en)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of preparing antibody by use of cell having its fucose transporter function inhibited
|
CA2592015A1
(en)
|
2004-12-27 |
2006-07-06 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally deliverable and anti-toxin antibodies and methods for making and using them
|
HUE026107T2
(en)
|
2004-12-28 |
2016-05-30 |
Innate Pharma |
Monoclonal antibodies against NKG2A
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
CA2595169A1
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
EP1870458B1
(en)
|
2005-03-31 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 STRUCTURAL ISOMERS
|
EP1871808A2
(en)
|
2005-03-31 |
2008-01-02 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
DK3050963T3
(en)
*
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Process for producing polypeptide by arrangement control
|
EP1876236B9
(en)
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
SG161281A1
(en)
|
2005-04-15 |
2010-05-27 |
Genentech Inc |
Hgf beta chain variants
|
JP5255435B2
(en)
|
2005-04-26 |
2013-08-07 |
メディミューン,エルエルシー |
Regulation of antibody effector function by hinge domain manipulation
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
EP3348639A3
(en)
|
2005-06-10 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Sc(fv)2 site-directed mutant
|
US9241994B2
(en)
|
2005-06-10 |
2016-01-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(Fv)2
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CN101627054A
(en)
|
2005-07-11 |
2010-01-13 |
马克罗基因公司 |
Method with the anti-CD16A Antybody therapy of humanization autoimmune disease
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
PL2407486T3
(en)
|
2005-08-19 |
2018-05-30 |
Wyeth Llc |
Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
|
JP2009510102A
(en)
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
Immunomodulatory compositions and uses thereof
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
RU2446826C2
(en)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Agents for suppressing transplanted island damage following island transplantation
|
EP1941908B1
(en)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for heart disease
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
JP4294082B2
(en)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
Agonist antibody to human thrombopoietin receptor
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
EP2025346B1
(en)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Muscle regeneration promoter
|
CL2007001665A1
(en)
|
2006-06-08 |
2008-01-18 |
Chugai Pharmaceutical Co Ltd |
Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.
|
JP2009541275A
(en)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
Production of bispecific antibodies
|
DK2059536T3
(en)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
OPTIMIZED ANTIBODIES AGAINST CD19
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
JPWO2008090960A1
(en)
|
2007-01-24 |
2010-05-20 |
協和発酵キリン株式会社 |
Recombinant antibody composition that specifically binds to ganglioside GM2
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
CN101679974B
(en)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
Comprise construct and the library of antibody surrogate light chain sequences
|
CN101802015B
(en)
|
2007-03-29 |
2015-05-06 |
根马布股份公司 |
Bispecific antibodies and methods for production thereof
|
US20100291023A1
(en)
|
2007-05-31 |
2010-11-18 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
EP4119579A1
(en)
|
2007-05-31 |
2023-01-18 |
Genmab A/S |
Stable igg4 antibodies
|
SI2178921T1
(en)
|
2007-07-17 |
2016-05-31 |
E.R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against glypican-3
|
EP2031064A1
(en)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Method for increasing protein titres
|
US8660800B2
(en)
*
|
2007-09-04 |
2014-02-25 |
Koninklijke Philips N.V. |
Multi-treatment planning apparatus and method
|
CA2698809C
(en)
|
2007-09-14 |
2023-10-17 |
Amgen Inc. |
Homogeneous antibody populations
|
MX369784B
(en)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
|
WO2009041734A1
(en)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
Agonistic antibody against human thrombopoietin receptor
|
WO2009041621A1
(en)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody
|
CA2700394C
(en)
|
2007-09-26 |
2017-10-24 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
DK2196541T3
(en)
|
2007-09-28 |
2012-11-26 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3 antibody with improved plasma kinetics
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
ES2400107T3
(en)
|
2007-10-22 |
2013-04-05 |
Merck Serono S.A. |
Single IFN-beta fused to an Fc fragment of mutated lgG
|
AU2008332271C1
(en)
|
2007-12-05 |
2014-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-NR10 antibody and use thereof
|
CA2706502C
(en)
|
2007-12-18 |
2018-08-07 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
PL2808343T3
(en)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
US20110059078A1
(en)
|
2008-02-08 |
2011-03-10 |
Medimmune, Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
CN107551270A
(en)
|
2008-04-11 |
2018-01-09 |
中外制药株式会社 |
The antigen binding molecules combined repeatedly with the antigen of multiple molecules
|
MX2010011717A
(en)
|
2008-05-01 |
2010-11-30 |
Amgen Inc |
Anti-hepcidin antibodies and methods of use.
|
BRPI0919382A2
(en)
|
2008-09-26 |
2016-01-05 |
Roche Glycart Ag |
anti-egfr / anti-igf-1r bispecific antibodies
|
TWI440469B
(en)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
KR101901458B1
(en)
|
2008-10-10 |
2018-09-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
TCR Complex immunotherapeutics
|
WO2010064090A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Process for the modulation of the antagonistic activity of a monoclonal antibody
|
AR074438A1
(en)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
PROCESS FOR THE MODULATION OF ANTAGONIST ACTIVITY OF A MONOCLONAL ANTIBODY
|
TWI646193B
(en)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
Antibody constant region alteration
|
WO2010107110A1
(en)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
Antibody constant region variant
|
EP2233500A1
(en)
*
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
US8882803B2
(en)
|
2009-04-01 |
2014-11-11 |
Globus Medical, Inc. |
Orthopedic clamp and extension rod
|
BRPI1010297A2
(en)
|
2009-04-07 |
2017-06-06 |
Roche Glycart Ag |
trivalent bispecific antibodies.
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
KR101747103B1
(en)
*
|
2009-06-26 |
2017-06-14 |
리제너론 파마슈티칼스 인코포레이티드 |
Readily isolated bispecific antibodies with native immunoglobulin format
|
CN102741288B
(en)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
DLL4 associated proteins is used in treatment
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
AU2010321720B2
(en)
|
2009-11-23 |
2017-03-02 |
Amgen Inc. |
Monomeric antibody Fc
|
KR101856792B1
(en)
|
2009-12-25 |
2018-05-11 |
추가이 세이야쿠 가부시키가이샤 |
Polypeptide modification method for purifying polypeptide multimers
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
EP2525822B1
(en)
|
2010-01-20 |
2017-05-10 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
TWI505838B
(en)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody
|
ES2602971T3
(en)
*
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Modified Antibody Composition
|
WO2011108714A1
(en)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
Antibody constant region variant
|
KR20150002894A
(en)
|
2010-03-11 |
2015-01-07 |
리나트 뉴로사이언스 코프. |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
TWI667346B
(en)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
Antibodies with modified affinity to fcrn that promote antigen clearance
|
WO2011125674A1
(en)
|
2010-03-31 |
2011-10-13 |
Jsr株式会社 |
Filler for affinity chromatography
|
SG10201800757TA
(en)
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
TWI586806B
(en)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
Production of heteromultimeric proteins
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013537416A
(en)
*
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
Monomer polypeptide containing mutant Fc region and method of use
|
PL2635607T3
(en)
*
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
RU2620071C2
(en)
|
2010-11-17 |
2017-05-22 |
Чугаи Сеияку Кабушики Каиша |
Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
|
RU2658504C9
(en)
|
2010-11-30 |
2018-08-21 |
Чугаи Сейяку Кабусики Кайся |
Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
|
JP6278598B2
(en)
|
2010-11-30 |
2018-02-14 |
中外製薬株式会社 |
Cell injury inducer
|
KR20230005405A
(en)
|
2011-02-25 |
2023-01-09 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb-specific Fc antibody
|
EP2688909A2
(en)
|
2011-03-25 |
2014-01-29 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
EP2699263A4
(en)
|
2011-04-20 |
2014-12-24 |
Liquidating Trust |
Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
|
CN103827300A
(en)
|
2011-06-30 |
2014-05-28 |
中外制药株式会社 |
Heterodimerized polypeptide
|
AU2012317418B2
(en)
|
2011-09-30 |
2017-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
TW201817744A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
SG10201805291TA
(en)
*
|
2011-10-27 |
2018-08-30 |
Genmab As |
Production of heterodimeric proteins
|
KR102168733B1
(en)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
CA2854233C
(en)
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2014067011A1
(en)
|
2012-11-02 |
2014-05-08 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
US20160046693A1
(en)
|
2012-02-24 |
2016-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
|
CA2860543C
(en)
|
2012-03-08 |
2018-04-24 |
F. Hoffmann-La Roche Ag |
Abeta antibody formulation
|
ES2728301T3
(en)
|
2012-03-13 |
2019-10-23 |
Novimmune Sa |
Easily isolated bispecific antibodies with native immunoglobulin format
|
WO2013147153A1
(en)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
Anti-lamp5 antibody and utilization thereof
|
MX366813B
(en)
|
2012-04-20 |
2019-07-25 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides.
|
MX360109B
(en)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Methods and means for the production of ig-like molecules.
|
TWI797443B
(en)
|
2012-05-30 |
2023-04-01 |
日商中外製藥股份有限公司 |
Screening or production method of antigen-binding molecule
|
CN104520331B
(en)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
High-affinity monoclonal antibody of glypican-3 and application thereof
|
WO2013187495A1
(en)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
EA028244B1
(en)
|
2012-08-13 |
2017-10-31 |
Ридженерон Фармасьютикалз, Инк. |
ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
|
NZ630563A
(en)
|
2012-09-27 |
2017-04-28 |
Merus Nv |
Bispecific igg antibodies as t cell engagers
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
CN103833852A
(en)
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen
|
ES2876009T3
(en)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Heterodimerized polypeptide
|
JP6449229B2
(en)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
FC variant
|
US11124576B2
(en)
|
2013-09-27 |
2021-09-21 |
Chungai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
JP6841596B2
(en)
|
2013-09-30 |
2021-03-10 |
中外製薬株式会社 |
Method for Producing Antigen-Binding Molecules Using Modified Helper Phage
|
CA2929256C
(en)
|
2013-11-04 |
2022-04-26 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
IL247715B
(en)
|
2014-04-07 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
TW201623333A
(en)
|
2014-05-13 |
2016-07-01 |
Chugai Pharmaceutical Co Ltd |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
TWI831106B
(en)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
JP6630036B2
(en)
|
2014-09-30 |
2020-01-15 |
Jsr株式会社 |
Method for purifying target substance and carrier for mixed mode
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
CN107454906B
(en)
|
2015-04-17 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
Combination therapy using coagulation factors and multispecific antibodies
|
JP2018123055A
(en)
|
2015-04-24 |
2018-08-09 |
公立大学法人奈良県立医科大学 |
Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi (fxi) abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii (fviii)
|
US9608835B2
(en)
|
2015-05-18 |
2017-03-28 |
Siang Pheng Ong |
Method and apparatus for creating a smart network
|
CA3004288A1
(en)
|
2015-12-28 |
2017-07-06 |
Nobuyuki Tanaka |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
TWI797073B
(en)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
Pharmaceutical composition comprising bispecific antibody constructs
|
MY196747A
(en)
|
2016-03-14 |
2023-05-03 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
TW202402326A
(en)
|
2016-04-28 |
2024-01-16 |
日商中外製藥股份有限公司 |
Antibody-containing preparation
|
US20210107994A1
(en)
|
2017-03-31 |
2021-04-15 |
Public University Corporation Nara Medical University |
Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
|